Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-04-16 DOI:10.1016/j.vaccine.2025.127093

Fan Zheng , Maokun Zhu , Hengdong Ran , Jiayi He , Binghan Bai , Simeng Feng , Wei Dong , Bin Li , Lixin Wen , Xiaomin Yuan

{"title":"Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.","authors":"Fan Zheng , Maokun Zhu , Hengdong Ran , Jiayi He , Binghan Bai , Simeng Feng , Wei Dong , Bin Li , Lixin Wen , Xiaomin Yuan","doi":"10.1016/j.vaccine.2025.127093","DOIUrl":null,"url":null,"abstract":"<div><div>Pseudorabies virus (PRV) causes high mortality encephalitis in newborn piglets, abortion and stillbirth in sows, resulting in huge economic losses to the swine industry. Interferon-induced transmembrane proteins (IFITMs) play a crucial role in the innate immune response triggered by viral infection. Lactic acid bacteria (LABs) are good candidates for the development of new oral vaccines and are attractive alternatives to attenuated pathogens. “Here we tested the capacity of a LAB vector expressing the IFITM3 protein (r-LAB-I3), delivered by oral gavage, to protect mice against PRV challenge. Furthermore, the r-LAB-I3 treated groups showed markedly diminished levels of viral DNA in brain, lung, spleen and liver tissues, which resulted in protection against brain and lung damage. Moreover, the inhibitory effect of IFITM3 on PRV circumvents the upregulation of inflammatory cytokines. As r-LAB-I3 oral gavage platforms can restrict in various organs and tissues of PRV in mice, recombinant LAB may generate additional innovative and efficient live vector anti-PRV candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127093"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25003901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pseudorabies virus (PRV) causes high mortality encephalitis in newborn piglets, abortion and stillbirth in sows, resulting in huge economic losses to the swine industry. Interferon-induced transmembrane proteins (IFITMs) play a crucial role in the innate immune response triggered by viral infection. Lactic acid bacteria (LABs) are good candidates for the development of new oral vaccines and are attractive alternatives to attenuated pathogens. “Here we tested the capacity of a LAB vector expressing the IFITM3 protein (r-LAB-I3), delivered by oral gavage, to protect mice against PRV challenge. Furthermore, the r-LAB-I3 treated groups showed markedly diminished levels of viral DNA in brain, lung, spleen and liver tissues, which resulted in protection against brain and lung damage. Moreover, the inhibitory effect of IFITM3 on PRV circumvents the upregulation of inflammatory cytokines. As r-LAB-I3 oral gavage platforms can restrict in various organs and tissues of PRV in mice, recombinant LAB may generate additional innovative and efficient live vector anti-PRV candidates.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.